 Despite the recent approval of Covid-19 vaccines, there is an urgent need for new vaccines due to slow access in poorer countries, and we propose a platform using recombinant receptor-binding domain, RBD, from SARS-CoV-2 spike protein and near Syria meningotidus outer membrane vesicles, OMVs, that produces a humeral and cellular immune response. This article was authored by Emanuel B. Gaspar, Carlos Roberto Prudentio and Elizabeth de Gasparri.